T
Tianchen Biotechnology
Design, development, and sales of ophthalmology-related medical products
About Tianchen Biotechnology
Based in Tianjin, China, Tianchen (Tianjin) Biotechnology Co., Ltd. is a privately held company established in 2018 that specializes in the research, development, production, and sale of ophthalmic medical devices. The firm directs its efforts toward creating high-tech solutions for unmet clinical needs within the eye care sector, manufacturing both active medical devices and passive consumable products. Its client base includes both individual patients, for whom it provides portable treatment and care equipment, and medical institutions, which are offered comprehensive diagnostic and therapeutic solutions.
The company's product lines are segmented into categories for glaucoma and dry eye treatment. A notable achievement for the company was securing the Class III Medical Device Registration Certificate for its Ophthalmic Intense Pulsed Light (IPL) Therapeutic Device in late 2024. This was followed by the pioneering implantation of its Minimally Invasive Glaucoma Drainage System at Beijing Tongren Hospital. The business model appears to focus on the direct sale of these specialized medical devices and consumables to healthcare providers and patients.
Financially, Tianchen Biotechnology is venture-backed and has completed multiple rounds of funding. In March 2024, the company raised $13.9 million in a Series A1 round, with CMB International Capital participating as an investor. The company's team includes talent from prominent institutions such as Tsinghua University, Beihang University, and Tianjin University, bringing together expertise in materials science, optics, and clinical ophthalmology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jun 2025 | $28M | $110M | Honghui Capital | ↗ |
| SERIES A✓Equity / VC | Mar 2024 | $14M | $55M | CMB International | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tianchen Biotechnology in the Heping District ecosystem
The Tianchen Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- CICMB International
Series B and later1 investor entered at this stage
- HCHonghui Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tianchen Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tianchen Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









